SCHEDULE: BlackRock Discloses 7.0% Stake in BIO-TECHNE Corporation
Beneficial Ownership Report
BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 7.0% beneficial ownership stake in BIO-TECHNE Corporation's common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 11,011,556 shares of BIO-TECHNE Corporation's common stock.
- This represents 7.0% of the total outstanding common shares of BIO-TECHNE Corporation.
- BlackRock holds sole voting power over 10,333,812 shares and sole dispositive power over 11,011,556 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries are identified as having acquired the security, with BlackRock Fund Managers Ltd specifically noted as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or forward-looking statements from the issuer.
Positives
- A significant stake by a major institutional investor like BlackRock can be interpreted as a vote of confidence in BIO-TECHNE Corporation's long-term prospects.
- BlackRock's stated intent to hold shares in the ordinary course of business, not for control, suggests a passive investment approach.
Future Outlook
NA
Industry Context
BlackRock, Inc. is one of the world's largest asset managers, and its filings of Schedule 13G indicate its significant passive investment positions in publicly traded companies as part of its various funds and portfolios. This filing reflects BlackRock's standard practice of disclosing beneficial ownership exceeding 5% in accordance with SEC regulations.
Stakeholder Impact
- Shareholders: BlackRock's 7.0% beneficial ownership represents a substantial institutional holding, which could provide stability and influence voting on certain matters, although BlackRock has certified that the shares were not acquired for the purpose of changing or influencing control of the issuer.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was revoked by the new one. |
| 2025-01-21 | Date of execution for the new Power of Attorney by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement, representing the reporting period end date for beneficial ownership calculation. |
| 2025-07-16 | Signature date of the Schedule 13G/A filing by BlackRock, Inc. |
Keywords
BlackRock, BIO-TECHNE Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.